Oculis to Present Privosegtor Data at Medical Conferences
The company will share neuroprotective findings for its optic neuritis drug candidate at upcoming international summits.
Updated on Oct. 29, 2026 in Stroke
Live Poll
Do you believe current drug development processes effectively prioritize the most urgent medical needs?
Oculis announced it will present new data on Privosegtor, a peptoid small-molecule candidate designed to cross retinal and blood-brain barriers, at two medical conferences. The presentations highlight findings from the ACUITY Phase 2 trial in patients with acute optic neuritis.
Why it matters
These presentations showcase the neuroprotective potential of Privosegtor, which has already received regulatory designations for treating optic neuritis. They serve to update the medical community on the drug's ongoing development and clinical progress.
The ACUITY Phase 2 trial demonstrated anatomical preservation of the retina and reductions in blood neurofilament levels in participants. Privosegtor has secured Breakthrough Therapy designation from the FDA and PRIority Medicines status from the EMA.
The players
Oculis
Based in Zug, Switzerland, this biopharmaceutical company focuses on developing innovative treatments for ophthalmic diseases.
Riad Sherif
As a lead representative for Oculis, he provides strategic overviews regarding the company's clinical research pipeline.
Aaron Tansy
He is a clinical researcher responsible for presenting the specific findings from the ACUITY trial.
The details
The drug is currently being evaluated in the PIONEER-1 trial for patients with acute-onset optic neuritis. Privosegtor is specifically engineered to penetrate blood-brain and retinal barriers to provide neuroprotection.
Timeline
October 30th - November 1st, 2026: The 6th Asia-Pacific Ophthalmic Innovation Society Congress takes place in Seoul.
November 1st, 2026: Riad Sherif presents an overview of Privosegtor.
November 1st - 4th, 2026: The CNS Summit is held in Everett, Massachusetts.
November 2nd - 3rd, 2026: Aaron Tansy presents ACUITY trial data.
Q4 2026: Anticipated clearance of an IND for multiple sclerosis relapses.
The Big Picture
This research follows the clinical trajectory set by the ongoing PIONEER-1 trial research program. The results reflect a broader industry shift toward developing small-molecule treatments that successfully cross the blood-brain barrier to treat neurodegenerative conditions.
These findings provide a path forward for patients suffering from acute optic neuritis who may benefit from new neuroprotective therapies. Success in these trials could eventually lead to expanded treatment options for patients with acute multiple sclerosis relapses.
The takeaway
Ongoing clinical presentations are critical for validating new drug candidates before they reach the commercial market. Patients and healthcare providers should monitor these updates as they signal potential shifts in standard care protocols for optic neuritis.
What happens next
Oculis expects to receive clearance for an Investigational New Drug application targeting the treatment of acute multiple sclerosis relapses in the fourth quarter of 2026.
Further reading
Learn more about the latest research in neurological recovery at World Stroke.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe current drug development processes effectively prioritize the most urgent medical needs?
